175 related articles for article (PubMed ID: 32641280)
1. Correlation between telomerase reverse transcriptase messenger RNA expression and survival of patients with papillary thyroid carcinoma.
Kwon JH; Yi JW
Surgery; 2021 Jan; 169(1):43-49. PubMed ID: 32641280
[TBL] [Abstract][Full Text] [Related]
2.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
3. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
Bu R; Siraj AK; Divya SP; Kong Y; Parvathareddy SK; Al-Rasheed M; Al-Obaisi KAS; Victoria IG; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
Int J Cancer; 2018 May; 142(10):2028-2039. PubMed ID: 29266240
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation.
Chien MN; Yang PS; Hsu YC; Liu TP; Lee JJ; Cheng SP
Head Neck; 2018 Nov; 40(11):2528-2537. PubMed ID: 30102829
[TBL] [Abstract][Full Text] [Related]
5. Low expression of
Yang L; Zhang X; Zhang J; Liu Y; Ji T; Mou J; Fang X; Wang S; Chen J
Future Oncol; 2022 Jan; 18(3):333-348. PubMed ID: 34756116
[TBL] [Abstract][Full Text] [Related]
6. A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence.
He J; Tian Z; Yao X; Yao B; Liu Y; Yang J
Clin Exp Metastasis; 2020 Apr; 37(2):257-267. PubMed ID: 31792675
[TBL] [Abstract][Full Text] [Related]
7. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis.
Cai WY; Chen X; Chen LP; Li Q; Du XJ; Zhou YY
J Cell Biochem; 2018 Nov; 119(10):8249-8259. PubMed ID: 29968931
[TBL] [Abstract][Full Text] [Related]
8. Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer.
Kim TH; Ki CS; Hahn SY; Oh YL; Jang HW; Kim SW; Chung JH; Shin JH
Endocrine; 2017 Aug; 57(2):234-240. PubMed ID: 28616852
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a ferroptosis-related prognostic model for the prediction of progression-free survival and immune microenvironment in patients with papillary thyroid carcinoma.
Huang Y; Xie Z; Li X; Chen W; He Y; Wu S; Li X; Hou B; Sun J; Wang S; He Y; Jiang H; Lun Y; Zhang J
Int Immunopharmacol; 2021 Dec; 101(Pt A):108156. PubMed ID: 34624650
[TBL] [Abstract][Full Text] [Related]
10. A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!
Juhlin CC
Scand J Surg; 2020 Sep; 109(3):187-192. PubMed ID: 31131695
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA signature predicts survival in papillary thyroid carcinoma.
Chengfeng X; Gengming C; Junjia Z; Yunxia L
J Cell Biochem; 2019 Oct; 120(10):17050-17058. PubMed ID: 31099134
[TBL] [Abstract][Full Text] [Related]
12. Advances in Detecting Low Prevalence Somatic
da Costa VR; Bim LV; Pacheco E Silva LDP; Colloza-Gama GA; Bastos AU; Delcelo R; Oler G; Cerutti JM
Front Endocrinol (Lausanne); 2021; 12():643151. PubMed ID: 33776938
[TBL] [Abstract][Full Text] [Related]
13. Identification of key genes and miRNAs markers of papillary thyroid cancer.
Qiu J; Zhang W; Zang C; Liu X; Liu F; Ge R; Sun Y; Xia Q
Biol Res; 2018 Nov; 51(1):45. PubMed ID: 30414611
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma.
Shen L; Qian C; Cao H; Wang Z; Luo T; Liang C
World J Surg Oncol; 2018 Dec; 16(1):235. PubMed ID: 30558624
[TBL] [Abstract][Full Text] [Related]
15. Associations of telomerase reverse transcriptase rs10069690 and rs2736100 polymorphisms with papillary thyroid carcinoma.
Liu Y; Shi F
Eur J Cancer Prev; 2020 May; 29(3):259-265. PubMed ID: 31651569
[TBL] [Abstract][Full Text] [Related]
16. A novel gene panel for prediction of lymph-node metastasis and recurrence in patients with thyroid cancer.
Ruiz EML; Niu T; Zerfaoui M; Kunnimalaiyaan M; Friedlander PL; Abdel-Mageed AB; Kandil E
Surgery; 2020 Jan; 167(1):73-79. PubMed ID: 31711617
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of long noncoding RNA MALAT1 in papillary thyroid cancer and its diagnostic value.
Liu J; Dong H; Yang Y; Qian Y; Liu J; Li Z; Guan H; Chen Z; Li C; Zhang K; Zhang Q; Cao W; Lv J
Future Oncol; 2018 Dec; 14(29):3015-3022. PubMed ID: 29987950
[TBL] [Abstract][Full Text] [Related]
18. Identification of key genes of papillary thyroid carcinoma by integrated bioinformatics analysis.
Xue G; Lin X; Wu JF; Pei D; Wang DM; Zhang J; Zhang WJ
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32766727
[TBL] [Abstract][Full Text] [Related]
19. Immune cell infiltrate-associated dysregulation of DNA repair machinery may predispose to papillary thyroid carcinogenesis.
Nicolson NG; Brown TC; Korah R; Carling T
Surgery; 2020 Jan; 167(1):66-72. PubMed ID: 31439400
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.
Nam SH; Bae MR; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2018 Dec; 87():158-164. PubMed ID: 30527232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
